Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype.

BACKGROUND In multiple sclerosis (MS), brain atrophy depicted by magnetic resonance imaging reflects overall tissue loss, including axonal loss. OBJECTIVE To determine the course of atrophy by studying the rate of development of brain atrophy in patients who have different subtypes of MS. METHODS Eighty-three patients with MS (42 with relapsing-remitting, 21 with secondary progressive, and 20 with primary progressive) were studied longitudinally, with an interval of 2 to 4 years. Magnetic resonance imaging included T1- and T2-weighted images to obtain 2 brain volume measurements: (1) the parenchymal fraction as a marker of global brain atrophy and (2) the ventricular fraction as a marker of central atrophy. The annualized rate of global and central brain atrophy was compared between those with different subtypes of MS and related to clinical characteristics, including sex, age, disease duration, and disability. RESULTS There was a significant decrease of the parenchymal fraction (-0.7% per year; SEM, 0.11% per year) and a significant increase of ventricular fraction (3.7% per year; SEM, 0.54% per year) in the total group. Significant tissue loss was also seen in all 3 subtypes of MS; the decrease in parenchymal fraction was not different between subtypes, whereas the increase in ventricular fraction tended to be larger in patients with secondary progressive MS compared with patients with primary progressive MS. Marginal associations were found between clinical determinants and the rate of brain atrophy. Annualized increase in the ventricular fraction was correlated with age (r = -0.26) and duration of symptoms (r = -0.22): younger patients (mainly patients with relapsing-remitting MS who have a limited disability) displayed a larger increase in ventricular fraction compared with older patients. CONCLUSIONS The rate of development of brain atrophy is largely independent of the course of the disease and other clinical characteristics. The relentless loss of tissue occurring in MS is not restricted to later (progressive) phases of the disease, thereby stressing the need for early neuroprotective treatment in MS.

[1]  T. Hammeke,et al.  Chronic progressive multiple sclerosis. Relationship between cerebral ventricular size and neuropsychological impairment. , 1985, Archives of neurology.

[2]  D. N. Landon,et al.  The characterization of experimental gliosis by quantitative nuclear magnetic resonance imaging. , 1988, Brain : a journal of neurology.

[3]  R. McGhee,et al.  Magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. , 1992, The Journal of neuropsychiatry and clinical neurosciences.

[4]  A J Thompson,et al.  Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. , 1996, Brain : a journal of neurology.

[5]  P M Matthews,et al.  Imaging axonal damage of normal-appearing white matter in multiple sclerosis. , 1998, Brain : a journal of neurology.

[6]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[7]  R. Herndon,et al.  A longitudinal study of brain atrophy in relapsing multiple sclerosis , 1999, Neurology.

[8]  R. Rudick,et al.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.

[9]  J. Simon.  From enhancing lesions to brain atrophy in relapsing MS , 1999, Journal of Neuroimmunology.

[10]  L D Blumhardt,et al.  Infratentorial atrophy on magnetic resonance imaging and disability in multiple sclerosis. , 1999, Brain : a journal of neurology.

[11]  F Barkhof,et al.  Neuronal damage in T1‐hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy , 1999, Annals of neurology.

[12]  A. Thompson,et al.  One year follow up study of primary and transitional progressive multiple sclerosis , 2000, Journal of neurology, neurosurgery, and psychiatry.

[13]  M N Rossor,et al.  Progressive cerebral atrophy in MS , 2000, Neurology.

[14]  J K Udupa,et al.  Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. , 2000, Radiology.

[15]  J. Duda,et al.  Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon β-1a , 2000, Multiple sclerosis.

[16]  Nick C Fox,et al.  Detection of ventricular enlargement in patients at the earliest clinical stage of MS , 2000, Neurology.

[17]  J. Udupa,et al.  The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS , 2000, Neurology.

[18]  G Cutter,et al.  Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. , 2000, Multiple sclerosis.

[19]  J K Udupa,et al.  Glatiramer acetate (Copaxone) treatment in relapsing–remitting MS , 2000, Neurology.

[20]  G J Barker,et al.  The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. , 2000, Brain : a journal of neurology.

[21]  A J Thompson,et al.  T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow‐up study , 2001, European journal of neurology.

[22]  G Cutter,et al.  Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS , 2001, Neurology.

[23]  F Barkhof,et al.  Optimizing the association between disability and biological markers in MS , 2001, Neurology.

[24]  G Cazzato,et al.  A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis , 2001, Journal of neurology, neurosurgery, and psychiatry.

[25]  C. Polman,et al.  A study validating changes in the multiple sclerosis functional composite. , 2002, Archives of neurology.